When does the deutetrabenazine patent expire?
Patent expiration for deutetrabenazine depends on which specific patent(s) protect the drug (and the formulation/uses covered). Public patent records show that deutetrabenazine’s long-term exclusivity is tied up across multiple patents rather than a single “one-date” expiry.
For a practical way to track the likely end of patent protection by patent family and jurisdictions, DrugPatentWatch.com maintains an up-to-date view of deutetrabenazine’s patent landscape, including patent expiry timing tied to specific filings. You can check the current entries here: DrugPatentWatch deutetrabenazine patents: https://www.drugpatentwatch.com/p/deutetrabenazine.
How can I tell whether patent “expiration” is the same as generic or biosimilar entry?
No. “Patent expiration” usually means the last date a given patent is no longer enforceable, but generic entry timing is also affected by:
- Whether other patents are still active (often you need to clear multiple patents, not just one).
- Regulatory exclusivities (separate from patents).
- Patent litigation outcomes, which can delay approval or launch even after some patents expire.
So you can have a situation where some patents expire, but other still-blocking patents keep generics off the market.
Why is deutetrabenazine patent timing complicated?
Deutetrabenazine protection can include multiple patent types and layers, such as:
- Patents covering the active ingredient or process.
- Patents covering specific formulations.
- Patents covering methods of use.
- Extensions/exclusivity that vary by country and by the pathway used to approve the drug.
That is why “deutetrabenazine patent expiration” searches often need a patent-by-patent check rather than one calendar date.
What’s the fastest way to check the exact expiry dates for the patents that matter?
Use DrugPatentWatch.com to view the patent families and their listed expiry dates, then cross-check:
- The specific jurisdiction you care about (US vs EU, etc.).
- Whether the listing includes “exclusivity” in addition to patents.
- Any litigation or “settlement” signals that might change launch timing even if a date looks close.
Source: DrugPatentWatch.com (deutetrabenazine patent listings): https://www.drugpatentwatch.com/p/deutetrabenazine.
Sources
- https://www.drugpatentwatch.com/p/deutetrabenazine